Nautilus Biotechnology (NAUT) Operating Leases (2020 - 2026)
Nautilus Biotechnology (NAUT) posted Operating Leases of $27.8 million for Q2 2026, down 3.66% sequentially from $28.9 million in Q1 2026, and down 1.3% YoY from $28.2 million in Q2 2025.
Nautilus Biotechnology (NAUT) Operating Leases (2020 - 2026) Analysis & Trends
Nautilus Biotechnology has reported Operating Leases for 7 years, with the latest figure at $27.8 million in Q2 2026.
- Quarterly Operating Leases fell 1.3% year-over-year to $27.8 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $27.8 million (down 1.3% YoY) and the FY2025 annual result came in at $26.2 million, down 0.74% from the prior year.
- Operating Leases eased to $27.8 million in Q2 2026 per NAUT's latest filing, from $28.9 million in the prior quarter.
- Over five years, Operating Leases peaked at $37.3 million in Q1 2023 and troughed at $26.2 million in Q4 2025.
- A 5-year average of $30.5 million and a median of $29.5 million in 2022 frame the typical range for Operating Leases.
- The sharpest annual moves came in 2022 and 2024: Operating Leases soared 2213.44% in 2022, then fell 15.15% in 2024.
- Over 5 years, Operating Leases stood at $28.3 million in 2022, then climbed by 9.72% to $31.1 million in 2023, then dropped by 15.15% to $26.4 million in 2024, then declined by 0.74% to $26.2 million in 2025, then grew by 6.22% to $27.8 million in 2026.
- According to Business Quant data, Operating Leases over the past three periods registered $27.8 million, $28.9 million, and $26.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.23 Bn | 132.38 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.97 Bn | 78.97 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.29 Bn | 60.11 Bn | 1.37 Bn |
| 4 | Moderna | 59.88 Bn | 54.74 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.20 Bn | 37.11 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.62 Bn | 28.31 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.69 Bn | 10.30 Bn | 668.28 Mn |
| 8 | Insmed | 27.51 Bn | 26.35 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.16 Bn | 26.33 Bn | - |
| 10 | Nautilus Biotechnology | 119.08 Mn | 119.08 Mn | 175,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 27.82 Mn |
| Mar 31, 2026 | 28.87 Mn |
| Dec 31, 2025 | 26.19 Mn |
| Sep 30, 2025 | 27.00 Mn |
| Jun 30, 2025 | 28.18 Mn |
| Mar 31, 2025 | 29.34 Mn |
| Dec 31, 2024 | 26.38 Mn |
| Sep 30, 2024 | 31.57 Mn |
| Jun 30, 2024 | 32.60 Mn |
| Mar 31, 2024 | 33.62 Mn |
| Dec 31, 2023 | 31.09 Mn |
| Sep 30, 2023 | 35.64 Mn |
| Jun 30, 2023 | 36.46 Mn |
| Mar 31, 2023 | 37.31 Mn |
| Dec 31, 2022 | 28.34 Mn |
| Sep 30, 2022 | 29.17 Mn |
| Jun 30, 2022 | 29.61 Mn |
| Mar 31, 2022 | 30.05 Mn |
| Dec 31, 2021 | 29.06 Mn |
| Sep 30, 2021 | 3.61 Mn |